Sutro Biopharma, Inc. (NASDAQ: STRO)

Sutro Biopharma, Inc., a company that trades under the symbol STRO on the NASDAQ stock exchange, is a clinical-stage oncology firm operating in the biotechnology industry. The company's primary business activities involve the development of site-specific and novel-format antibody drug conjugates (ADCs) using its proprietary integrated cell-free protein synthesis platform, XpressCF, and site-specific conjugation platform, XpressCF+. Sutro Biopharma operates in the United States, with its headquarters located in South San Francisco, California.

The company generates revenue through the development of ADCs for cancer treatment. Sutro Biopharma's most advanced product candidate is STRO-002, an ADC directed against folate receptor-alpha (FolRα) for patients with FolRα-expressing cancers, including ovarian cancer. STRO-002, also known as luveltamab tazevibulin or luvelta, has shown promising preliminary efficacy data in a Phase 1 trial and has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Sutro Biopharma's XpressCF platform addresses the challenges of ADCs by enabling the incorporation of non-natural amino acids into antibody sequences and resulting in site-specific conjugation of drug payloads. The platform also allows for the development of dual conjugation approaches, which combine pharmacology into a single molecule, and ADC2 modalities, which combine two payloads to offset resistance mechanisms.

The company's position within the industry is strengthened by its competitive advantages, such as its XpressCF platform, which differentiates Sutro Biopharma from its competitors. The company's key competitors include ImmunoGen, Seattle Genetics, and ADC Therapeutics.

Sutro Biopharma's product candidates have shown potent antitumor activity and potential for a differentiated safety profile. The company's pipeline of product candidates includes STRO-003, a single homogeneous ADC directed against ROR1 for patients with ROR1-expressing tumors, and STRO-004, a single homogeneous ADC directed against TF for patients with TF-expressing tumors.

The company's XpressCF platform has been used to develop a pipeline of novel product candidates, including ADCs, iADCs, ADC2s, and engineered cytokines. Sutro Biopharma's Discovery and Preclinical stage programs include the discovery of novel ADCs using the XpressCF platform, the development of cytokine-based immuno-oncology therapeutics, and the development of engineered cytokines for the treatment of cancer.

In addition to ADCs, Sutro Biopharma is also exploring cytokine-based immuno-oncology therapeutics, which have shown promise in the treatment of cancer. The company's collaboration with Merck has yielded an IL-2 derivative that entered Phase 1 in 2022.

Sutro Biopharma has several collaborations and license agreements in place, including a collaboration with Merck, Astellas, and Tasly. These collaborations have the potential to generate significant revenue for the company through milestone payments and royalties.

The company's revenue is generated from the development of its product candidates and collaborations with other firms. Sutro Biopharma's customers include pharmaceutical and biotechnology companies, as well as cancer patients.